Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03117140 · ClinicalTrials.gov registry record · Phase 4
Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block
A Phase 4 study, sponsored by Melinda Seering.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT03117140: Completed Phase 4 study, sponsored by Melinda Seering.
NCT03117140 is a Phase 4 study that has completed, run by Melinda Seering. The registered enrollment target is 160 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03117140, a Phase 4 study, has completed, sponsored by Melinda Seering.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.
Primary Outcome
Patients are called 1-3 days post-operatively to assess when the analgesia of their nerve block wore off
Interventions
- DRUG Ropivacaine 0.75%
- DRUG Ropivacaine 0.75% + 300 mcg Buprenorphine
- DRUG Ropivacaine 0.75% + 75 mcg clonidine
- DRUG Ropivacaine 0.75% + 8 mg dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 4 |
What the finished NCT03117140 record still lists
NCT03117140 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 4 interventions - of which Ropivacaine 0.75% is the first listed.
NCT03117140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03117140 about?
NCT03117140 is a clinical study titled "Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block". This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.
What is the current status of trial NCT03117140?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2013-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT03117140?
The interventions under investigation include: Ropivacaine 0.75% (DRUG), Ropivacaine 0.75% + 300 mcg Buprenorphine (DRUG), Ropivacaine 0.75% + 75 mcg clonidine (DRUG), Ropivacaine 0.75% + 8 mg dexamethasone (DRUG).
Who is sponsoring clinical trial NCT03117140?
This trial is sponsored by Melinda Seering, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03117140's enrollment target sits among peer trials
160 507th of 2000 higher than 1,485 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia